Prostate cancer patients who undergo therapy to decrease testosterone levels increase their risk of developing bone- and heart-related side effects compared to patients who do not take these medications, according to a new analysis.
Published in the June 1, 2009 issue of CANCER , a peer-reviewed journal of the American Cancer Society, the study indicates that preventive measures and careful scrutiny of patients' health can keep men from experiencing these potentially serious consequences.
While medical treatments that decrease testosterone levels - called androgen deprivation therapy (ADT) - are important and effective therapies or men with prostate cancer, they can cause a variety of side effects including skeletal and cardiovascular complications, sexual dysfunction, periodontal disease, and mood disorders.
Bone and heart complications are among the most serious side effects associated with ADT, but the actual risk patients have of developing these effects is unknown. Lockwood Taylor, MPH, of the University of Texas Health Science Center and colleagues conducted a study to assess this risk by analyzing all of the literature related to side effects from ADT published between 1996 and mid-2008. They found 14 studies (8 bone-related, 6 heart-related) that were suitable for analysis.